Eli Lilly and Co. and MacroGenics Inc. announced that the Protege Data Monitoring Committee (DMC), has completed a planned analysis of one-year safety and efficacy data of the Protege Phase 3 clinical trial of teplizumab.
The DMC, composed of independent experts in the fields of diabetes and biostatistics, concluded that the primary efficacy endpoint of the study was not met...